BioSpace News Archive

Evoke Pharma, Inc. today announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI, the Company’s novel treatment solution meant to treat symptoms associated with acute and recurrent diabetic gastroparesis.

Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2023, the period ended April 30, 2022.

To fulfill the growing need of Colorectal Cancer Screening organizations and big clinical laboratories, Sentinel Diagnostics announces the launch of the SENTiFIT® 800 Analyzer, a fully automated and high throughput system for Fecal Immunochemical Test.

Orion Corporation has entered into an agreement with Belgian private company Inovet BV to acquire its wholly owned subsidiary V.M.D. NV and all companies belonging to V.M.D. NV’s group of companies.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that it will host an industry-sponsored lunch symposium on Targeted Alpha Therapies for cancer treatment at the 6th Theranostics World Congress, held from June 24 to 26 in Wiesbaden, Germany.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the emirate, joined the A.Catalyst network as a result of the Declaration of Collaboration recently signed with AstraZeneca.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Professor René Bernards to its Board of Directors.

Creative Medical Technology Holdings, Inc., a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell pipeline for the Company’s ImmCelz® platform.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022:

Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA ® (inebilizumab) in Brazil.